SELLAS Life Sciences Group (SLS) Equity Average: 2011-2024
Historic Equity Average for SELLAS Life Sciences Group (SLS) over the last 7 years, with Sep 2024 value amounting to $9.4 million.
- SELLAS Life Sciences Group's Equity Average rose 1750.89% to $9.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $9.4 million, marking a year-over-year increase of 1750.89%. This contributed to the annual value of -$1.6 million for FY2023, which is 112.40% down from last year.
- SELLAS Life Sciences Group's Equity Average amounted to $9.4 million in Q3 2024, which was up 49.28% from $6.3 million recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences Group's Equity Average registered a high of $31.1 million during Q2 2021, and its lowest value of -$5.9 million during Q4 2023.
- Moreover, its 3-year median value for Equity Average was $9.0 million (2023), whereas its average is $7.0 million.
- In the last 5 years, SELLAS Life Sciences Group's Equity Average plummeted by 167.65% in 2023 and then soared by 1,750.89% in 2024.
- Over the past 5 years, SELLAS Life Sciences Group's Equity Average (Quarterly) stood at $18.0 million in 2020, then surged by 30.76% to $23.5 million in 2021, then tumbled by 62.84% to $8.7 million in 2022, then plummeted by 167.65% to -$5.9 million in 2023, then soared by 1,750.89% to $9.4 million in 2024.
- Its Equity Average stands at $9.4 million for Q3 2024, versus $6.3 million for Q2 2024 and $854,000 for Q1 2024.